Colon cancer blood test offers new screening option
A blood test for colon cancer performed well in a study published Wednesday, offering a new kind of screening for a leading cause of cancer deaths.
The test looks for DNA fragments shed by tumor cells and precancerous growths. It’s already for sale in the U.S. for $895, but has not been approved by the Food and Drug Administration and most insurers do not cover it. The maker of the test, Guardant Health, anticipates an FDA decision this year.
In the study, the test caught 83% of the cancers but very few of the precancerous growths found by colonoscopy, the gold standard for colon cancer screening. Besides spotting tumors, colonoscopies can prevent the disease by removing precancerous growths called polyps.
But some people avoid the exam because of the hassle of getting time off work or the day-ahead preparation that involves drinking a strong laxative to empty the bowels.
Related articles
EU, Finnish leaders call for de
European Commission President Ursula von der Leyen and Finnish Prime Minister Petteri Orpo on Friday2024-05-01Guizhou Achieves Progress in Economic Development, Poverty Alleviation
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-01Rural Women in SW China's Guizhou Make Creative Cultural Products to Increase Income
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-01China Moves to Further Integrate Medical and Elderly Care Services
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-01Hamas official says no agreement with Israel if war continues in Gaza
An official of the Palestinian Islamic Resistance Movement (Hamas) said on Sunday that the movement2024-05-01China Contributes over 30 Pct to World Economic Growth in 2013
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-01
atest comment